 No detectable tuftsin-related toxicity was noticed in human patients during a phase II study, where the peptide was injected intravenously twice a week at total doses of 5 mg per injection.Tuftsin deficiency can be hereditary or can occur following splenectomy, resulting in increased susceptibility to certain diseases e.g.